From pharmaceutical stocks to dividend-payers, these are the ASX shares that have caught my eye this week.
Image source: Getty Images
Mesoblast Ltd (ASX: MSB)
Mesoblast is a clinical-stage biotech company which develops and commercialises allogeneic cellular medicines to treat complex diseases. Its FDA-approved Ryoncil® product is in the market and the company is also in the process of developing other cellular medicines to treat other complex conditions. Some are already in the latter stages of their clinical trial pipelines.
The company is well-positioned for growth and said it can draw additional capital from its convertible note facility as it continues to grow sales and broaden its cell therapy pipeline for other inflammatory conditions.
At the time of writing Mesoblast shares are up 2.89% for the day at $2.85 a piece. Analyst consensus is that there is a strong upside ahead for Mesoblast shares, with some forecasting a target price of $5.25. This implies the shares could hike another 84.11% over the next 12 months.
Plato Income Maximiser Ltd (ASX: PL8)
When it comes to income-generating stocks, I like the look of Plato right now. The ASX dividend share holds a portfolio of mature ASX-listed equities, cash, and listed futures. Its portfolio is mostly Australian companies with strong dividend payouts, which is very well diversified and liquid by design.
Plato has consistently paid fully franked dividends of 0.55 cents per share every month since April 2022. The company said that it plans to keep its dividends steady going forward too, even amid market uncertainty. Plato is currently trading at $1.45 per share.
Telix Pharmaceuticals Ltd (ASX: TLX)
The beaten-down stock has suffered multiple setbacks this year. Regulatory issues and broker downgrades have dampened investor sentiment. At the time of writing the ASX biotech company's shares have plunged another 7.56% to $11.61 a piece.
I think the tide is about to turn Telix though. The company has already had huge success with its flagship prostate cancer imaging product, Illuccix. Once it receives approval for Zircaix, it has the potential to open the door to another long road of growth.
Analysts are very bullish too. Most have a buy or strong buy rating on the shares and think the shares could climb as high as $34.30 over the next 12 months. That's a huge potential 195.53% upside. It looks like today's crash could be a great buying opportunity.
Zip Co Ltd (ASX: ZIP)
It's been a year of ups and downs for the Australian financial technology company. But Zip has shown strong and improved earnings this year, and the company is continually pushing for even more growth. The business is actively broadening its product range and is also looking at ways to scale its US presence.
I think there is still some good momentum ahead for Zip shares. Analysts are mostly bullish on the stock and think the share price could climb as high as $6.20 in 2026. Using the $3.01 share price at the time of writing, that implies a massive potential 106.32% upside.
Telstra Corporation Ltd (ASX: TLS)
Telstra has been in the spotlight for a while now, and triple-0 concerns and buyback programs have dented its share price recently. At the time of writing the shares are $4.81 a piece.
But I like that Telstra is a defensive stock. The company tends to perform steadily, regardless of the stage of the economic cycle. And this is great news for investors who want to hedge against potential volatility elsewhere.
The company has performed well this year and has outlined some great growth plans for 2026. I'm optimistic that these can be executed. Analysts are also mostly bullish. They expect the share price could rise as high as $5.40, which implies a potential 12.38% upside for investors at the time of writing.
